Drugs / SA55
SA55
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06050460 | Jun → Oct 2023 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06048393 | May → Sep 2023 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06042764 | Aug 2023 → Mar 2024 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05675943 | Jan 2023 → Apr 2024 | COVID-19, hematologic disorder | Beijing Boren Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-12-15 | Sinovac Biotech Co., Ltd | Results 对多种奥密克戎变异株广谱有效 新冠病毒广谱单克隆抗体为防治带来新希望 sinovac.com ↗
体外中和试验和动物模型研究显示，SA58和SA55无论单独使用或同时使用均具有作为针对新冠病毒的广谱性治疗或预防用药的潜在价值。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-12-15 | Sinovac Biotech Co., Ltd | 对多种奥密克戎变异株广谱有效 新冠病毒广谱单克隆抗体为防治带来新希望 sinovac.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SA55 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06042764 ↗ |
| Known as | BD55-5514 | “covering BD series SARS-CoV-2 monoclonal antibodies, including BD55-5840 (SA58) and BD55-5514 (SA55), that lists Y.C. as the inventor.” PMID 40673766 ↗ Jul 2025 |
| Known as | SA55 Injection | “Drug: SA55 Injection” NCT06042764 ↗ |
| Action | Inhibit | “Novel coronavirus broad-spectrum neutralizing antibody SA55 injection” NCT06042764 ↗ |
| Modality | Protein / enzyme biologic | “novel coronavirus broad-spectrum neutralizing antibody” NCT06048393 ↗ |
| Route | Intramuscular | “given the corresponding drug by intramuscular injection once” NCT05675943 ↗ |